The sales of Chong Kun Dang pharm are expected to register two digit growth in the second half of this year.
kiwoom Securities forecast on 23 July that the sales of Chong Kun Dang would record 89.4 billion won in the second half of 2009, up 17.2 % compared with the same period of 2008(76.3 billion won), thanks to its new drugs such as 'Salotan' and 'Salotan-plus' (Cozaar generics) sales growth.
According to Kiwoom Securitie' analysis report, the sales of its Cozaar generics are expected to record 13.0 billion won only in the first half of this year and a total of 25.0~30.0 billion won in 2009.
However, In the second half of this year, the operating profit of Chong Kun Dang is anticipated to be 10.4 billion won, down 7.3% compared with the same period of 2008(11.1 billion won).
The main reasons of the decline in its operating profit are as follows: the skyrocketing exchange rate and the increase of its sales promotion costs due to strengthened marketing for bluckbuster generics released in the second half of last year. <헬스코리아뉴스>
▶ 종근당, 판촉비 절감으로 하반기 이익 급증<애널리스트 창>
